Management of Poststroke Hyperglycemia: Results of the TEXAIS Randomized Clinical Trial

CF Bladin; N Wah Cheung; HM Dewey; L Churilov; S Middleton; V Thijs; E Ekinci; CR Levi; R Lindley; GA Donnan; MW Parsons; A Meretoja; M Tiainen; PMC Choi; D Cordato; H Brown; BCV Campbell; SM Davis; G Cloud; R Grimley; M Lee-Archer; D Ghia; L Sanders; R Markus; C Muller; P Salvaris; T Wu; J Fink

Journal article

Management of Poststroke Hyperglycemia: Results of the TEXAIS Randomized Clinical Trial

CF Bladin, N Wah Cheung, HM Dewey, L Churilov, S Middleton, V Thijs, E Ekinci, CR Levi, R Lindley, GA Donnan, MW Parsons, A Meretoja, M Tiainen, PMC Choi, D Cordato, H Brown, BCV Campbell, SM Davis, G Cloud, R Grimley Show all

Stroke | LIPPINCOTT WILLIAMS & WILKINS | Published : 2023

DOI: 10.1161/STROKEAHA.123.044568

Open access

Abstract

BACKGROUND: Hyperglycemia in acute ischemic stroke reduces the efficacy of stroke thrombolysis and thrombectomy, with worse clinical outcomes. Insulin-based therapies are difficult to implement and may cause hypoglycemia. We investigated whether exenatide, a GLP-1 (glucagon-like peptide-1) receptor agonist, would improve stroke outcomes, and control poststroke hyperglycemia with minimal hypoglycemia. METHODS: The TEXAIS trial (Treatment With Exenatide in Acute Ischemic Stroke) was an international, multicenter, phase 2 prospective randomized clinical trial (PROBE [Prospective Randomized Open Blinded End-Point] design) enrolling adult patients with acute ischemic stroke ≤9 hours of stroke ons..

View full abstract

University of Melbourne Researchers

Leonid Churilov Author

Vincent Thijs Author

Elif Ekinci Author

Geoffrey Donnan Author

Related Projects (1)

POST-STROKE HYPERGLYCAEMIA – TREATMENT WITH EXENATIDE IN ACUTE ISCHAEMIC STROKE (TEXAIS) TRIAL

Raised blood glucose levels (hyperglycaemia) after a stroke is common. It reduces the efficacy of stroke treatments and results in worse out..

Grants

Funding Acknowledgements

The TEXAIS (Treatment With Exenatide in Acute Ischemic Stroke) was supported by research grant 1126070 from the National Health and Medical Research Council of Australia. The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. Material support from Medtronic in the use of Medtronic iPro2 Professional Continuous Glucose Monitors.